Browsing Tag
GLP-1R
2 posts
Can Ascletis’ obesity pipeline redefine oral and monthly peptide therapy in 2026?
Find out how Ascletis’ oral and monthly obesity therapies are challenging industry norms with next-gen peptide technology.
Why investors are watching Ascletis Pharma’s monthly obesity shot as a potential GLP-1 disruptor
Ascletis Pharma reveals ASC36–ASC35 obesity combo with 51% greater weight loss vs tirzepatide. IND filing expected in 2026. Learn what’s next in its pipeline.